NYSE:CLB Core Laboratories (CLB) Stock Price, News & Analysis → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free CLB Stock Alerts $17.07 +0.54 (+3.27%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$16.47▼$17.9250-Day Range$14.11▼$17.8952-Week Range$13.82▼$27.94Volume691,836 shsAverage Volume467,827 shsMarket Capitalization$799.90 millionP/E Ratio19.85Dividend Yield0.23%Price Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Core Laboratories alerts: Email Address Core Laboratories MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside8.4% Upside$18.50 Price TargetShort InterestBearish12.86% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.04Based on 22 Articles This WeekInsider TradingN/AProj. Earnings Growth36.25%From $0.80 to $1.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsOils/Energy Sector177th out of 234 stocksOil & Gas Field Services, Not Elsewhere Classified Industry12th out of 18 stocks 0.8 Analyst's Opinion Consensus RatingCore Laboratories has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 2 hold ratings, and 2 sell ratings.Amount of Analyst CoverageCore Laboratories has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.86% of the float of Core Laboratories has been sold short.Short Interest Ratio / Days to CoverCore Laboratories has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Core Laboratories has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldCore Laboratories has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthCore Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Core Laboratories is 4.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Core Laboratories will have a dividend payout ratio of 3.67% next year. This indicates that Core Laboratories will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLB. Previous Next 2.2 News and Social Media Coverage News SentimentCore Laboratories has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Oils/Energy companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Core Laboratories this week, compared to 3 articles on an average week.Search Interest7 people have searched for CLB on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Core Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Core Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.76% of the stock of Core Laboratories is held by insiders.Percentage Held by Institutions97.81% of the stock of Core Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Core Laboratories are expected to grow by 36.25% in the coming year, from $0.80 to $1.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Core Laboratories is 19.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Core Laboratories is 19.85, which means that it is trading at a more expensive P/E ratio than the Oils/Energy sector average P/E ratio of about 18.57.Price to Earnings Growth RatioCore Laboratories has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioCore Laboratories has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Core Laboratories Stock (NYSE:CLB)Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.Read More CLB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLB Stock News HeadlinesApril 25, 2024 | finanznachrichten.deCore Laboratories Inc: Core Lab Reports First Quarter 2024 ResultsApril 25, 2024 | msn.comCore Laboratories declares $0.01 dividendApril 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!April 25, 2024 | investorplace.comCLB Stock Earnings: Core Laboratories Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | msn.comCore Laboratories Non-GAAP EPS of $0.07 misses by $0.08, revenue of $129.6M beats by $5.14MApril 24, 2024 | prnewswire.comCORE LAB REPORTS FIRST QUARTER 2024 RESULTSApril 22, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for Core Laboratories Inc.'s FY2025 Earnings (NYSE:CLB)April 20, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Core Laboratories Inc. (NYSE:CLB) Cut by AnalystApril 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!April 17, 2024 | finance.yahoo.comEarnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to DeclineApril 17, 2024 | americanbankingnews.comCore Laboratories (CLB) Scheduled to Post Quarterly Earnings on WednesdayApril 16, 2024 | americanbankingnews.comCore Laboratories (NYSE:CLB) Given New $16.00 Price Target at Bank of AmericaApril 8, 2024 | msn.comHC asks Centre, NABL to reply to PIL on labs illegally collecting samples, giving false reportsApril 4, 2024 | msn.comState-of-the-art specialist school to be in North-East for students with autismMarch 28, 2024 | msn.comGovernor Abbott appoints Ronnie Keister to Texas County And District Retirement System Board Of TrusteesMarch 28, 2024 | msn.comThese 2024 irons improve toe misses, according to robot testingMarch 28, 2024 | msn.comLDCC holds ribbon cutting for new Medical Technicians LaboratoryMarch 28, 2024 | msn.comLabcorp Expands Diagnostic Reach With Strategic Deal For Select Assets Of BioReference HealthMarch 26, 2024 | finance.yahoo.comCORE LABORATORIES' FIRST QUARTER 2024 WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 25, 2024March 21, 2024 | finance.yahoo.comShareholders in Core Laboratories (NYSE:CLB) are in the red if they invested five years agoMarch 18, 2024 | finance.yahoo.comCore Laboratories Inc.: Growing International and Offshore Markets Continue to Boost Demand for Core Labs' ServicesMarch 15, 2024 | ca.finance.yahoo.comQ4 2023 Evoke Pharma Inc Earnings CallMarch 15, 2024 | theguardian.comAngela Rayner says she wants to see Diane Abbott get Labour whip restored – as it happenedMarch 14, 2024 | msn.comLow-cost lab works helps everyone “know their numbers”March 11, 2024 | finance.yahoo.comCore Laboratories (CLB) Fell on Mixed Earnings ResultsFebruary 27, 2024 | finance.yahoo.comCore Laboratories (CLB) Fell Due to Weak US Land DrillingFebruary 23, 2024 | bizjournals.comLeadership shakeup at Yuga Labs after co-founder reclaims CEO roleSee More Headlines Receive CLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Core Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/4 Dividend2/09/2024Dividend Payable3/04/2024Last Earnings4/24/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorOils/Energy Industry Oil & gas field services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSE:CLB CUSIPN/A CIK1000229 Webwww.corelab.com Phone(713) 328-2673FaxN/AEmployees3,600Year Founded1936Price Target and Rating Average Stock Price Target$18.50 High Stock Price Target$21.00 Low Stock Price Target$16.00 Potential Upside/Downside+6.8%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.86 Trailing P/E Ratio20.14 Forward P/E Ratio21.65 P/E Growth0.96Net Income$36.67 million Net Margins8.03% Pretax Margin8.08% Return on Equity15.19% Return on Assets5.62% Debt Debt-to-Equity Ratio0.71 Current Ratio2.53 Quick Ratio1.72 Sales & Book Value Annual Sales$509.79 million Price / Sales1.59 Cash Flow$1.08 per share Price / Cash Flow16.01 Book Value$4.92 per share Price / Book3.52Miscellaneous Outstanding Shares46,860,000Free Float46,508,000Market Cap$811.62 million OptionableOptionable Beta2.40 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Lawrence V. Bruno (Age 63)Chairman of the Board, CEO, President & COO Comp: $1.47MMr. Christopher Scott Hill (Age 54)Senior VP & CFO Comp: $668.8kMs. Gwendolyn Y. Gresham M.B.A. (Age 56)Senior Vice President of Corporate Development & Investor Relations Comp: $574.19kMr. Mark Damian Tattoli (Age 52)Senior VP, Secretary & General Counsel Comp: $565.11kMr. Kevin G. Daniels (Age 60)Chief Accounting Officer, Treasurer & VP Mr. Jacobus Schouten (Age 69)Managing Director Comp: $26.35kJ. Donald Dumas Jr.Senior VP of Production Enhancement & Business DevelopmentMore ExecutivesKey CompetitorsNational Energy Services ReunitedNASDAQ:NESRProPetroNYSE:PUMPProFracNASDAQ:PFHCCSI CompresscoNASDAQ:CCLPNatural Gas Services GroupNYSE:NGSView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 400 shares on 4/25/2024Ownership: 0.000%KLR Investment Advisors LLCSold 835 shares on 4/23/2024Ownership: 0.024%Norden Group LLCBought 23,086 shares on 4/19/2024Ownership: 0.049%Congress Wealth Management LLC DE Bought 53,090 shares on 4/18/2024Ownership: 0.391%Congress Asset Management Co. MABought 240,989 shares on 4/11/2024Ownership: 3.429%View All Institutional Transactions CLB Stock Analysis - Frequently Asked Questions Should I buy or sell Core Laboratories stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Core Laboratories in the last year. There are currently 2 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" CLB shares. View CLB analyst ratings or view top-rated stocks. What is Core Laboratories' stock price target for 2024? 4 brokerages have issued 1-year price targets for Core Laboratories' shares. Their CLB share price targets range from $16.00 to $21.00. On average, they expect the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View analysts price targets for CLB or view top-rated stocks among Wall Street analysts. How have CLB shares performed in 2024? Core Laboratories' stock was trading at $17.66 at the beginning of 2024. Since then, CLB shares have decreased by 3.3% and is now trading at $17.07. View the best growth stocks for 2024 here. Are investors shorting Core Laboratories? Core Laboratories saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 5,970,000 shares, a decrease of 9.4% from the March 31st total of 6,590,000 shares. Based on an average daily trading volume, of 453,200 shares, the days-to-cover ratio is currently 13.2 days. Approximately 12.9% of the shares of the stock are sold short. View Core Laboratories' Short Interest. When is Core Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our CLB earnings forecast. How were Core Laboratories' earnings last quarter? Core Laboratories Inc. (NYSE:CLB) released its earnings results on Wednesday, April, 24th. The oil and gas company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The oil and gas company earned $129.64 million during the quarter, compared to the consensus estimate of $124.47 million. Core Laboratories had a trailing twelve-month return on equity of 15.19% and a net margin of 8.03%. How often does Core Laboratories pay dividends? What is the dividend yield for Core Laboratories? Core Laboratories announced a quarterly dividend on Wednesday, January 31st. Investors of record on Monday, February 12th will be paid a dividend of $0.01 per share on Monday, March 4th. This represents a $0.04 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Friday, February 9th. Read our dividend analysis for CLB. Is Core Laboratories a good dividend stock? Core Laboratories (NYSE:CLB) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.24%. The dividend payout ratio is 4.65%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CLB will have a dividend payout ratio of 3.67% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CLB. What ETFs hold Core Laboratories' stock? ETFs with the largest weight of Core Laboratories (NYSE:CLB) stock in their portfolio include Cultivar ETF (CVAR), Invesco S&P SmallCap Energy ETF (PSCE), SPDR S&P Oil & Gas Equipment & Services ETF (XES), iShares U.S. Oil Equipment & Services ETF (IEZ) and Direxion Daily Oil Services Bull 2X Shares (ONG).VanEck Oil Services ETF (OIH). What guidance has Core Laboratories issued on next quarter's earnings? Core Laboratories updated its second quarter 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of 0.190-0.230 for the period, compared to the consensus EPS estimate of 0.210. The company issued revenue guidance of $130.0 million-$136.0 million, compared to the consensus revenue estimate of $130.1 million. What is David M. Demshur's approval rating as Core Laboratories' CEO? 60 employees have rated Core Laboratories Chief Executive Officer David M. Demshur on Glassdoor.com. David M. Demshur has an approval rating of 36% among the company's employees. This puts David M. Demshur in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Core Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Core Laboratories investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Starbucks (SBUX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Endologix (ELGX), Intel (INTC), Netflix (NFLX), AT&T (T) and Gilead Sciences (GILD). Who are Core Laboratories' major shareholders? Core Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (3.43%), Congress Wealth Management LLC DE (0.39%), Confluence Investment Management LLC (0.31%), Partnership Wealth Management LLC (0.27%), Ridgewood Investments LLC (0.07%) and Norden Group LLC (0.05%). View institutional ownership trends. How do I buy shares of Core Laboratories? Shares of CLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CLB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Core Laboratories Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
